Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer

Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer

Abstract Background OMT-110 is a repositioned drug candidate for the treatment of metastatic colorectal cancer (mCRC). This phase I study aimed to determine the appropriate dose of OMT-110 for phase II trials and its safety, tolerability, and efficacy. We conducted the first-in-human dose-escalation...

Full description

Saved in:
Bibliographic Details
Main Authors: Youngbae Jeon, MinJeong Jung, BongHwang Jeong, Haejun Lee, Sun Jin Sym, Jeong-Heum Baek
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
OMT-110
Colorectal neoplasm
Neoplasm metastasis
Phase I
Safety
Chemotherapy
Online Access:https://doi.org/10.1186/s12885-025-14351-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items